Literature DB >> 11355932

Chemotherapy resistance in acute myeloid leukaemia.

P Sonneveld1, A F List.   

Abstract

The development of refractory disease in acute myeloid leukaemia (AML) is frequently associated with the expression of one or several multidrug resistance (MDR) genes. MDR1, MRP1 and LRP have been identified as important adverse prognostic factors in AML. Recently it has become possible to reverse clinical multidrug resistance by blocking P-glycoprotein-mediated drug efflux. The potential relevance of MDR and new approaches to treat refractory disease, are discussed. Copyright 2001 Harcourt Publishers Ltd.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11355932     DOI： 10.1053/beha.2000.0124

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN： 1521-6926            Impact factor:   3.020


  7 in total

1.  Cyclosporine modulation of multidrug resistance in combination with pravastatin, mitoxantrone and etoposide for adult patients with relapsed/refractory acute myeloid leukemia: a phase 1/2 study.

Authors:  Tara L Chen; Elihu H Estey; Megan Othus; Kelda M Gardner; Lauren J Markle; Roland B Walter
Journal:  Leuk Lymphoma       Date:  2013-03-27

2.  Randomized use of cyclosporin A (CsA) to modulate P-glycoprotein in children with AML in remission: Pediatric Oncology Group Study 9421.

Authors:  David Becton; Gary V Dahl; Yaddanapudi Ravindranath; Myron N Chang; Fred G Behm; Susana C Raimondi; David R Head; Kimo C Stine; Norman J Lacayo; Branimir Ivan Sikic; Robert J Arceci; Howard Weinstein
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

Review 3.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

Review 4.  Oncology stewardship in acute myeloid leukemia.

Authors:  Madeleine A Ochs; Bernard L Marini; Anthony J Perissinotti; Charles E Foucar; Kristen Pettit; Patrick Burke; Dale L Bixby; Lydia L Benitez
Journal:  Ann Hematol       Date:  2022-05-26       Impact factor: 4.030

5.  Expression of MDR1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma.

Authors:  Heidi Schwarzenbach
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

6.  Hyperforin inhibits Akt1 kinase activity and promotes caspase-mediated apoptosis involving Bad and Noxa activation in human myeloid tumor cells.

Authors:  Faten Merhi; Ruoping Tang; Marion Piedfer; Julie Mathieu; Isabelle Bombarda; Murhaf Zaher; Jean-Pierre Kolb; Christian Billard; Brigitte Bauvois
Journal:  PLoS One       Date:  2011-10-06       Impact factor: 3.240

7.  P-Glycoprotein Activity at Diagnosis Does Not Predict Therapy Outcome and Survival in Canine B-Cell Lymphoma.

Authors:  Valéria Dékay; Edina Karai; András Füredi; Kornélia Szebényi; Gergely Szakács; Péter Vajdovich
Journal:  Cancers (Basel)       Date:  2022-08-13       Impact factor: 6.575
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.